Amgen (NASDAQ:AMGN) Releases Quarterly Earnings Results

Amgen (NASDAQ:AMGN) issued its quarterly earnings results on Thursday. The medical research company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20, Briefing.com reports. The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.98 earnings per share. Amgen updated its FY24 guidance to $19.00 to $20.20 EPS.

Amgen Trading Up 11.8 %

NASDAQ:AMGN opened at $311.29 on Friday. The business’s 50-day moving average is $274.51 and its two-hundred day moving average is $281.33. The firm has a market capitalization of $166.97 billion, a PE ratio of 24.92, a price-to-earnings-growth ratio of 2.68 and a beta of 0.60. Amgen has a 12 month low of $211.71 and a 12 month high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 2.89%. Amgen’s dividend payout ratio is currently 72.06%.

Analyst Ratings Changes

Several research firms have commented on AMGN. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday. Oppenheimer reaffirmed an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a research report on Thursday, February 1st. Royal Bank of Canada reduced their target price on Amgen from $332.00 to $328.00 and set an “outperform” rating on the stock in a research report on Friday. TD Cowen decreased their price target on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Finally, StockNews.com raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $305.05.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.46% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.